Investor Alert

New York Markets Close in:

Market Pulse Archives

April 16, 2018, 9:11 a.m. EDT

Dynavax shares rise 14% on promising cancer conference data

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Dynavax Technologies Corp. (DVAX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Emma Court

Dynavax Technologies Corp. /zigman2/quotes/203017054/composite DVAX -0.34% shares rose 14% in premarket trade Monday after the company released promising data in conjunction with the annual American Association for Cancer Research meeting, happening this week. New results for the company's immuno-oncology drug SD-101 "showed a promising 40% [overall response rate] indicative of potential activity in this difficult-to-treat setting" of head/neck cancers, said RBC Capital Markets analyst Brian Abrahams. Another abstract from the company showed "encouraging" durability of responses to SD-101 in melanoma, he noted. "Though the data do not necessarily answer the question as to whether these patients were somehow easier to treat than those in historical studies, the consistency over time is at least directionally encouraging, in our view," Abrahams said. Dynavax shares have surged 34.8% over the last three months but slumped 0.5% month-to-date, compared with a 4.3% decline in the S&P 500 /zigman2/quotes/210599714/realtime SPX +2.05% over the last three months and a 0.6% month-to-date rise.

US : U.S.: Nasdaq
$ 11.75
-0.04 -0.34%
Volume: 1.57M
May 26, 2022 2:36p
P/E Ratio
Dividend Yield
Market Cap
$1.49 billion
Rev. per Employee
+81.42 +2.05%
Volume: 1.51B
May 26, 2022 2:36p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.